Eye scans detected cell loss earlier in people with glaucoma
Retinal cell density fell 4.16 to 6.86% annually in glaucoma, compared with a 0.27% cell loss rate in healthy volunteers.

Our read
Biomarkers- Studied:
- Cohort study of people with glaucoma and healthy volunteers, 3 to 5 years
- What changed:
- High-resolution eye scans detected cell loss 0.74 years before conventional OCT in people with glaucoma
- The catch:
- AO-OCT measurements were more frequent than conventional OCT and visual field tests
- In the record:
- The 164th paper on glaucoma with results in people; 557 on record in all.
Editor of record: Boris Djordjevic · AgingResearch.News
People with glaucoma and healthy volunteers had individual retinal ganglion cells tracked for 3 to 5 years in a preliminary observational study. These nerve cells carry visual signals from the eye to the brain. The researchers used adaptive optics–optical coherence tomography, a high-resolution imaging method.
Retinal cell density decreased by 4.16 to 6.86% annually in people with glaucoma. Healthy volunteers had a 0.27% cell loss rate. The high-resolution method detected cell loss 0.74 years before conventional optical coherence tomography, a retinal imaging test, and 1.49 years before visual field testing, which measures the area a person can see.
Why it matters
Distinguishing glaucoma-related nerve cell loss from normal aging is important for monitoring this cause of irreversible blindness.
Caveats
Earlier detection of cell loss does not show that using these scans would preserve vision. The abstract does not give participant numbers, limiting assessment of how broadly the results apply.
Where the evidence stands
Cell killing (cytotoxicity)
- 58 independent labs in 20 countries
- 1 finding against
- Funders: National Institutes of Health and others
- 12 of 67 findings with company ties
The paper
On-going retinal neuronal degeneration despite clinical stability in glaucoma
Center for Devices and Radiological Health (CDRH)
Science Advances, Nov 4, 2026, Open access

Comments
Be the first to comment.